DOCSLIB.ORG

9186400.Pdf (2.851Mb)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
9186400.Pdf (2.851Mb) US009186400B2 (12) United States Patent (10) Patent No.: US 9,186,400 B2 Dickeyet al. (45) Date of Patent: Nov. 17, 2015 (54) COMPOSITIONS FOR STIMULATION OF 5,268,376 A 12/1993 Gester MAMMALIAN INNATE IMMUNE 5,346,905 A 9/1994 Gerster 5,352,784 A 10/1994 Nikolaideset al. RESISTANCE TO PATHOGENS 5,389,640 A 2/1995 Gersteret al. .. 5,395,937 A 3/1995 Nikolaidesetal. (71) Applicant: The Board of Regents, The University 5,432,157 A 7/1995 Metzgeretal. of Texas System, Austin, TX (US) 5,458,135 A 10/1995 Patton etal. 5,494,916 A 2/1996 Lindstrom etal. (72) Inventors: Burton Dickey, Houston, TX (US); 5,525,612 A 6/1996 Gerster Michael Tuvim, Houston, TX (US); 5,700,910 A 12/1997 Metzgeretal. ’ ° ’ 6,024,964 A 2/2000 Jungetal. Scott Evans, Houston, TX (US) 6,039,969 A 3/2000 Tomaietal. 6,066,447 A 5/2000 De Mesmaekeretal. (73) Assignee: The Board of Regents, The University 6,110,929 A 8/2000 Gersteret al. of Texas System, Austin, TX (US) 6,214,806 Bl 4/2001 Krieg et al. occ 514/44 ° ° 6,218,371 Bl 4/2001 Krieg et al. (*) Notice: Subject to any disclaimer, the term of this O88049 BI job! nee patent is extended or adjusted under 35 6,294,177 Bl 9/2001 Fattom U.S.C. 154(b) by 0 days. 6,331,539 BL 12/2001 Crookset al. 6,339,068 Bl 1/2002 Krieg et al. (21) Appl. No.: 14/519,834 6,406,705 Bl 6/2002 Davis et al. ° 6,429,199 Bl 8/2002 Krieget al. 514/44 : 6,451,810 Bl 9/2002 Coleman etal. (22) Filed: Oct. 21, 2014 6.488.953 B2 12/2002 Halliday et al. ; . 6,517,839 BL 2/2003 Modliret al. (65) Prior Publication Data 6,534,062 B2 3/2003 Razetal. 6,552,006 B2 4/2003 Raz etal. US 2015/0125492 Al May 7, 2015 6,727,230 B1 4/2004 Hutchersonet al. 6,737,045 B2 5/2004 Patton etal. Related U.S. Application Data 6,794,357 Bl 9/2004 Backstrom etal. 6,797,258 B2 9/2004 Platz et al. (62) Division of application No. 13/259,761, filed as 6,815,429 B2 11/2004 Agrawal et al. application No. PCT/US2010/028658 on Mar. 25, 6,929,798 B2 8/2005 Pillich et al. 2010. now Pat. No. 8.883.174. 6,949,520 Bl 9/2005 Hartmann etal. ; _— 6,977,245 B2 12/2005 Klinman et al. (60) Provisional application No. 61/179,246,filed on May Continued 18, 2009, provisional application No. 61/163,137, (Continued) filed on Mar. 25, 2009. FOREIGN PATENT DOCUMENTS (51) Int. Cl. EP 1550 458 7/2005 A6IK 39/39 (2006.01) EP 1 707 232 8/2010 A6IK 9/00 (2006.01) (Continued) A6IK 45/06 (2006.01) AGIK 38/08 (2006.01) OTHER PUBLICATIONS A6IK 31/7125 (2006.01) A6IK 39/00 (2006.01) Merkuset al. Rhinology, 44, 102-107, 2006.* (52) U.S. CI. Abuchowski et al., “Effect of covalent attachment of polyethylene CPC wee A6IK 39/39 (2013.01); A61LK 9/0078 glycol on immunogenicity and circulating life of bovine liver (2013.01); A6LK 31/7125 (2013.01); A61K catalase,” J. Biol. Chem., 252:3582-6, 1977. 38/08 (2013.01); A6LK 45/06 (2013.01); A6GIK Adachiet al., “Targeted disruption of the MyD88generesults in loss 2039/54 (2013.01); AGIK 2039/55561 of IL-1- and IL-18- mediated function,” Jmmunity, 9:143-150, 1998. (2013.01) (Continued) (58) Field of Classification Search None See application file for complete search history. Primary Examiner — Oluwatosin Ogunbiyi (74) Attorney, Agent, or Firm — Norton Rose Fulbright US (56) References Cited LLP U.S. PATENT DOCUMENTS 3,608,066 A 9/1971 Illartein (57) ABSTRACT 4,406,889 A 9/1983 Hartmann etal. .. 4,406,890 A 9/1983 Taresayet al. Embodiments of the invention are directed to methods of 4,423,038 A 12/1983 Baschangetal. treating, inhibiting or attenuating a microbial infection in an teeate ‘ 3ony Busty etal. poe any7a individual whohasoris at risk for developing suchan infec- 4668218;; A 5/1987 Virtanenaschang et al. oo... tion,: comprisinga the step of administeringss . an effective. 4.689 338 A 8/1987 Gerster amountof a StIR compositionto the individual. 4,929,624 A 5/1990 Gersteret al. 5,238,944 A 8/1993 Wicket al. 5,266,575 A 11/1993 Gerster et al. 20 Claims, 20 Drawing Sheets US 9,186,400 B2 Page 2 (56) References Cited 2004/0171571 Al 9/2004 Krieget al. 2004/0181045 Al 9/2004 Krieg et al. U.S. PATENT DOCUMENTS 2004/0198680 Al 10/2004 Krieg et al. 2004/0198688 Al 10/2004 Krieg et al. 7,001,890 Bl 2/2006 Wagneret al. 2004/0229835 Al 11/2004 Krieg etal. 7,038,029 B2 5/2006 Lopez etal. 2004/0234512 Al 11/2004 Wagneret al. 7,105,495 B2 9/2006 Agrawaletal. 2004/0235770 Al 11/2004 Davisetal. 7,115,579 B2 10/2006 Agrawaletal. 2004/0235777 Al 11/2004 Wagneret al. 7,157,437 B2 1/2007 NESt cecccccccccccecesecesesseeseceee 514/44 2004/0235778 Al 11/2004 Wagneretal. 7,176,296 B2 2/2007 Agrawaletal. 2004/0248834 Al 12/2004 Klinman etal. 7,271,156 B2 9/2007 Krieget al. 2004/0248837 Al 12/2004 Razetal. 7,276,489 B2 10/2007 Agrawaletal. 2005/0004061 Al 1/2005 Kriegetal. — 7,276,515 B2 10/2007 Dellariaet al. 2005/0004062 Al 1/2005 Krieg et al. 7.329.409 B2 2/2008 Pillich etal. 2005/0009774 Al 1/2005 Krieg etal. 7358068 B2 4/2008 Vaillantet al. 2005/0013812 Al 1/2005 Dowetal. 7.371.734 B2 5/2008 Phillips etal. 2005/0026861 Al 2/2005 Kandimalla etal. 7,381,807 B2 6/2008 Lopezetal. 2005/0032734 Al 2/2005 Krieg etal. 7.393.859 B2 7/2008 Coleman etal. 2005/0037403 Al 2/2005 Krieg et al. 7,402,572 B2 7/2008 Krieg etal. 2005/0043529 Al 2/2005. Kriegetal. —- 7.405.204 B2 7/2008 Robertsetal. 2005/0049215 Al 3/2005 Krieg etal. 7,405,285 B2 7/2008 Agrawaletal. 2005/0049216 Al 3/2005. Kriegetal. 7.408.050 B2 8/2008 Kimetal. 2005/0054601 Al 3/2005 Wagneretal. 7.410.975 B2 8/2008. Lipford etal. 2005/0054602 Al 3/2005 Krieg et al. 7.425.548 B2 9/2008 Nairet al. 2005/0059619 Al 3/2005 Krieg etal. 7,427,405 B2 9/2008 Agrawal etal. 2005/0059625 Al 3/2005. Kriegetal. 7.427.629 B2 9/2008 Kedl et al. 2005/0075302 Al 4/2005 Hutchersonet al. 7488490 B2 2/2009. Daviset al. 2005/0100983 Al 5/2005 Baueret al. 7401-706 B2 2/2009 Yuetal. 2005/0101554 Al §/2005. Kriegetal. _ 7,498,425 B2 3/2009 Agrawalet al. 2005/0107297 Al 5/2005 Holmeset al. 7,498,426 B2 3/2009 Agrawaletal. 2005/0119273 Al 6/2005 Lipford etal. 7.507.802 B2 3/2009 Ahn etal. 2005/0123523 Al 6/2005 Krieg et al. 7,517,861 B2 4/2009 Krieg etal. 2005/0130911 Al 6/2005 Uhlmannet al. 7,521,063 B2 4/2009 Klinman et al. 2005/0130918 Al 6/2005 Agrawal etal. 7.534.772 B2 5/2009 Weineret al. 2005/0163764 Al 7/2005 Medzhitovet al. 7,544,697 B2 6/2009 Haysetal. 2005/0169888 Al 8/2005 Hartmann etal. 7.550.501 B2 6/2009 Chowetal. 2005/0171047 Al 8/2005 Krieget al. 7,566,702 B2 7/2009 Agrawalet al. 2005/0181422 Al 8/2005 Baueret al. 7,566,703 B2 7/2009 Krieget al. 2005/0214359 Al 9/2005 Stegmann 7,569,553 B2 8/2009 Krieg etal. 2005/0215500 Al 9/2005 Krieg et al. 7,576,066 B2 8/2009 Krieg et al. 2005/0215501 Al 9/2005 Lipford etal. 7,585,847 B2 9/2009 Bratzleret al. 2005/0222072 Al 10/2005 Wanget al. 7,598,382 B2 10/2009 Haysetal. 2005/0233995 Al 10/2005 Krieg etal. 7,605,138 B2 10/2009 Krieget al. 2005/0239733 Al 10/2005 Jurk etal. 7,612,083 B2 11/2009 Griesgraberetal. 2005/0239734 Al 10/2005 Uhlmannetal. 7,615,539 B2 11/2009 Uhlmann etal. 2005/0239735 Al 10/2005 Miller et al. 7,713,529 B2 5/2010 Kriegetal. ..... 424/184.1 2005/0239736 Al 10/2005 Kriegetal. 7,723,022 B2 5/2010 Krieg et al. occ 435/5 2005/0244379 Al 11/2005 Krieg et al. 7,884,083 B2 2/2011 Van Nestetal... 514/44 2005/0244380 Al 11/2005 Kriegetal. 8,158,592 B2 4/2012 Krieg et al. .. .. 514/44 2005/0244505 Al 11/2005 Higbeeetal. 8,158,768 B2 4/2012 Dinaetal. ... .. 536/23.1 2005/0245477 Al 11/2005 Krieg et al. 8,226,957 B2 7/2012 Van Nest ..... A24/211.1 2005/0256073 Al 11/2005 Lipford etal. 8,283,328 B2 10/2012 Krieg etal. .. .. 514/44 2005/0261215 Al 11/2005 Garren etal. 8,309,527 B2 11/2012 Kriegetal. .. .. 514/44 2005/0276789 Al 12/2005 Lopezetal. 8,518,905 B2 8/2013. Hackam etal. 514/44 2005/0277604 Al 12/2005 Krieg et al. 8,871,732 B2 10/2014 Dinaetal. ccs 514/44 2005/0277609 Al 12/2005 Kriegetal. 2002/0045737 Al 4/2002 Choietal. 2005/0287612 Al 12/2005 Bertin et al. 2002/0142977 Al 10/2002 Razetal. 2006/0003955 Al 1/2006 Krieg et al.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,993,581 B2 Perrine Et Al
    US00899.3581B2 (12) United States Patent (10) Patent No.: US 8,993,581 B2 Perrine et al. (45) Date of Patent: Mar. 31, 2015 (54) METHODS FOR TREATINGVIRAL (58) Field of Classification Search DSORDERS CPC ... A61K 31/00; A61K 31/166; A61K 31/185: A61K 31/233; A61K 31/522: A61K 38/12: (71) Applicant: Trustees of Boston University, Boston, A61K 38/15: A61K 45/06 MA (US) USPC ........... 514/263.38, 21.1, 557, 565, 575, 617; 424/2011 (72) Inventors: Susan Perrine, Weston, MA (US); Douglas Faller, Weston, MA (US) See application file for complete search history. (73) Assignee: Trustees of Boston University, Boston, (56) References Cited MA (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this 3,471,513 A 10, 1969 Chinn et al. patent is extended or adjusted under 35 3,904,612 A 9/1975 Nagasawa et al. U.S.C. 154(b) by 0 days. (Continued) (21) Appl. No.: 13/915,092 FOREIGN PATENT DOCUMENTS (22) Filed: Jun. 11, 2013 CA 1209037 A 8, 1986 CA 2303268 A1 4f1995 (65) Prior Publication Data (Continued) US 2014/OO45774 A1 Feb. 13, 2014 OTHER PUBLICATIONS Related U.S. Application Data (63) Continuation of application No. 12/890,042, filed on PCT/US 10/59584 Search Report and Written Opinion mailed Feb. Sep. 24, 2010, now abandoned. 11, 2011. (Continued) (60) Provisional application No. 61/245,529, filed on Sep. 24, 2009, provisional application No. 61/295,663, filed on Jan. 15, 2010. Primary Examiner — Savitha Rao (74) Attorney, Agent, or Firm — Nixon Peabody LLP (51) Int.
    [Show full text]
  • Newer Trends in the Management of Genital Herpes
    Review NNewerewer trendstrends inin thethe mmanagementanagement ofof genitalgenital herpesherpes Article AAmiyamiya KKumarumar NNath,ath, DDevinderevinder MohanMohan ThappaThappa Department of Dermatology ABSTRACT and STD, Jawaharlal Institute of Postgraduate Medical Management of genital herpes is complex. Apart from using the standard antivirals, an Education and Research (JIPMER), Pondicherry - 605 ideal management protocol also needs to address various aspects of the disease, including 006, India the psychological morbidity. Oral acyclovir, valacyclovir or famciclovir are recommended for routine use. Long-term suppressive therapy is effective in reducing the number of AAddressddress forfor ccorrespondence:orrespondence: recurrences and the risk of transmission to others. Severe or disseminated disease may Dr. Devinder Mohan Thappa, require intravenous therapy. Resistant cases are managed with foscarnet or cidofovir. Genital Department of Dermatology herpes in human immunodeÞ ciency virus-infected individuals usually needs a longer duration and STD, JIPMER, of antiviral therapy along with continuation of highly active anti retroviral therapy (HAART). Pondicherry - 605 006, India. E-mail: [email protected] Genital herpes in late pregnancy increases the risk of neonatal herpes. Antiviral therapy and/or cesarean delivery are indicated depending on the clinical circumstance. Acyclovir appears to be safe in pregnancy. But, there is limited data regarding the use of valacyclovir and famciclovir in pregnancy. Neonatal herpes requires a higher dose of acyclovir given intravenously for a longer duration. Management of the sex partner, counseling and prevention advice are equally important in appropriate management of genital herpes. Vaccines till date have been marginally effective. Helicase–primase inhibitors, needle-free mucosal vaccine and a new microbicide product named VivaGel may become promising treatment options in the future.
    [Show full text]
  • The Effects of Atopy and Asthma on in Vivo Human Nasal Responses to Toll
    The effects of atopy and asthma on in vivo human nasal responses to Toll-like receptor agonists Dr Akhilesh Jha A thesis submitted for the degree of Doctor of Philosophy (PhD) Centre for Respiratory Infection National Heart and Lung Institute (NHLI), St Mary’s Campus Imperial College London, Norfolk Place, London W2 1PG July 2018 Abstract Acute respiratory viral infections cause significant morbidity and mortality, especially in vulnerable individuals, and it is important to study viral pathogenesis and the host immune response in humans. Toll-like receptors (TLRs) play a critical role in the detection of viral nucleic acids, and airway TLR receptors respond to nucleic acid patterns in the RNA viruses that cause respiratory infections. However, a reliable method of measuring mucosal innate immune responses to viral infections is lacking. TLR3 agonists (poly(I:C) and poly-ICLC) and the combined TLR7/8 agonist (resiquimod, R848) are synthetic analogues of double stranded RNA (dsRNA) and single stranded RNA (ssRNA) respectively. Nasal challenge with these TLR agonists was carried out, and serial sampling using nasosorption and nasal curettage was performed. Mucosal immune responses were measured and the effect of different host factors (e.g. asthma) on these responses was studied. Poly(I:C) and poly-ICLC were well tolerated but failed to induce significant and reliable nasal mucosal innate immune responses. R848 at a higher dose (10 µg/100 µL per nostril) induced significant mucosal interferon and cytokine responses but caused mild to moderate flu-like symptoms in three out of nine volunteers. A lower dose of R848 (0.02 µg/kg/100 µL, mean dose 1.5 µg/100 µL) was subsequently utilised in three groups of volunteers: healthy non-atopic (n=12), allergic rhinitis (n=12) and allergic asthma (n=11).
    [Show full text]
  • Inclusion and Exclusion Criteria for Each Key Question
    Supplemental Table 1: Inclusion and exclusion criteria for each key question Chronic HBV infection in adults ≥ 18 year old (detectable HBsAg in serum for >6 months) Definition of disease Q1 Q2 Q3 Q4 Q5 Q6 Q7 HBV HBV infection with infection and persistent compensated Immunoactive Immunotolerant Seroconverted HBeAg HBV mono-infected viral load cirrhosis with Population chronic HBV chronic HBV from HBeAg to negative population under low level infection infection anti-HBe entecavir or viremia tenofovir (<2000 treatment IU/ml) Adding 2nd Stopped antiviral therapy antiviral drug Interventions and Entecavir compared Antiviral Antiviral therapy compared to continued compared to comparisons to tenofovir therapy therapy continued monotherapy Q1-2: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Intermediate outcomes (if evidence on clinical outcomes is limited or unavailable): HBsAg loss, HBeAg seroconversion and Outcomes HBeAg loss Q3-4: Cirrhosis, decompensated liver disease, HCC, relapse (viral and clinical) and HBsAg loss Q5: Renal function, hypophosphatemia and bone density Q6: Resistance, flare/decompensation and HBeAg loss Q7: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Study design RCT and controlled observational studies Acute HBV infection, children and pregnant women, HIV (+), HCV (+) or HDV (+) persons or other special populations Exclusions such as hemodialysis, transplant, and treatment failure populations. Co treatment with steroids and uncontrolled studies. Supplemental Table 2: Detailed Search Strategy: Ovid Database(s): Embase 1988 to 2014 Week 37, Ovid MEDLINE(R) In-Process & Other Non- Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials August 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2014 Search Strategy: # Searches Results 1 exp Hepatitis B/dt 26410 ("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or 2 178548 "hepatitis type B").mp.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Bioinformatics Review of the Role of HSV-1 in Alzheimer's Disease
    Advances in Alzheimer’s Disease, 2020, 9, 57-75 https://www.scirp.org/journal/aad ISSN Online: 2169-2467 ISSN Print: 2169-2459 Bioinformatics Review of the Role of HSV-1 in Alzheimer’s Disease Brian T. Reiss1, Meade C. Eggleston1, Arah C. Godbole1, Julia A. Marut1, Cecelia M. McCann1, Jessica A. Cottrell1, Tinchun Chu1, Sulie L. Chang1,2* 1Department of Biological Sciences, Seton Hall University, South Orange, NJ, USA 2Institute of Neuroimmune Pharmacology, Seton Hall University, South Orange, NJ, USA How to cite this paper: Reiss, B.T., Eg- Abstract gleston, M.C., Godbole, A.C., Marut, J.A., McCann, C.M., Cottrell, J.A., Chu, T.C. and Alzheimer’s disease (AD) is a neurodegenerative disease characterized by the Chang, S.L. (2020) Bioinformatics Review progressive loss of cognitive functions in affected individuals. Brain tissue of the Role of HSV-1 in Alzheimer’s Dis- pathology is associated with the formation of senile plaques which result from ease. Advances in Alzheimer’s Disease, 9, 57-75. the over-production of amyloid β (Aβ), due to the cleavage of a membrane https://doi.org/10.4236/aad.2020.93005 bound glycoprotein. It is unclear what causes AD and its associated patholo- gies, but age and genetic predisposition play an import role in the likelihood Received: June 11, 2020 Accepted: September 6, 2020 of disease development. Studies have shown that the reactivation of latent Published: September 9, 2020 herpes simplex virus 1 (HSV-1) infection can lead to the neuropathy of acute herpes simplex encephalitis (HSE), which causes similar symptoms to AD.
    [Show full text]
  • A Screening-Based Approach to Circumvent Tumor Microenvironment
    JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Activation of Anti-Hepatitis C Virus Responses Via Toll-Like Receptor 7
    Activation of anti-hepatitis C virus responses via Toll-like receptor 7 Jongdae Lee*, Christina C. N. Wu*†, Ki Jeong Lee‡, Tsung-Hsien Chuang§, Kyoko Katakura*, Yu-Tsueng Liu*†, Michael Chan†, Rommel Tawatao†, Michelle Chung*, Carol Shen*, Howard B. Cottam†, Michael M. C. Lai‡, Eyal Raz*, and Dennis A. Carson†¶ *Department of Medicine, University of California at San Diego, La Jolla, CA 92093-0663; †Moores Cancer Center, University of California at San Diego Medical Center, La Jolla, CA 92093-0820; ‡Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033; and §Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037 Contributed by Dennis A. Carson, December 15, 2005 IFN-␣ is used to suppress the replication of hepatitis C virus (HCV) in HCV replicon cells. The IRFs can both foster type I IFN in chronically infected patients with partial success. Here we production (18) and enhance the antiviral activity of these present evidence showing that a ligand of Toll-like receptor 7 cytokines (19). Thus, pharmacologic agents that activate IRFs in (TLR7) can induce anti-HCV immunity not only by IFN induction, but hepatocytes may exert direct anti-HCV effects, as well as po- also through an IFN-independent mechanism. Human hepatocyte tentiate IFN action. line Huh-7 carrying an HCV replicon expressed TLR7, and activation Pharmacologic inhibitors of the enzyme inosine monophos- of the receptor induced several antiviral genes including IFN phate dehydrogenase (IMPDH), including ribavirin and mizor- regulatory factor-7. Inhibitors of the enzyme inosine monophos- ibine, have been reported to have activity against RNA viruses phate dehydrogenase augmented both IFN-dependent and -inde- (18–20).
    [Show full text]
  • Annual Report 2016
    Annexes to the annual report of the European Medicines Agency 2016 Annex 1 – Members of the Management Board ............................................................... 2 Annex 2 - Members of the Committee for Medicinal Products for Human Use ...................... 4 Annex 3 – Members of the Pharmacovigilance Risk Assessment Committee ........................ 6 Annex 4 – Members of the Committee for Medicinal Products for Veterinary Use ................. 8 Annex 5 – Members of the Committee on Orphan Medicinal Products .............................. 10 Annex 6 – Members of the Committee on Herbal Medicinal Products ................................ 12 Annex 7 – Committee for Advanced Therapies .............................................................. 14 Annex 8 – Members of the Paediatric Committee .......................................................... 16 Annex 9 – Working parties and working groups ............................................................ 18 Annex 10 – CHMP opinions: initial evaluations and extensions of therapeutic indication ..... 24 Annex 10a – Guidelines and concept papers adopted by CHMP in 2016 ............................ 25 Annex 11 – CVMP opinions in 2016 on medicinal products for veterinary use .................... 33 Annex 11a – 2016 CVMP opinions on extensions of indication for medicinal products for veterinary use .......................................................................................................... 39 Annex 11b – Guidelines and concept papers adopted by CVMP in 2016 ...........................
    [Show full text]
  • Naive Alum | IMQ-Cpg
    US010485861B2 United States Patent (10 ) Patent No.: US 10,485,861 B2 Stary et al. (45 ) Date of Patent : Nov. 26 , 2019 (54 ) NANOPARTICLE -BASED COMPOSITIONS Related U.S. Application Data ( 71) Applicants : President and Fellows of Harvard (60 ) Provisional application No. 61/ 783,439 , filed on Mar. College , Cambridge , MA (US ) : 14 , 2013 . Massachusetts Institute of (51 ) Int. CI. Technology , Cambridge , MA (US ); The A61K 39/118 (2006.01 ) Brigham and Women's Hospital, Inc., A61K 45/06 ( 2006.01) Boston , MA (US ) (Continued ) (52 ) U.S. CI. (72 ) Inventors : Georg Stary, Brookline, MA (US ) ; CPC A61K 39/118 (2013.01 ) ; A61K 31/4745 Aleksandar Filip Radovic -Moreno , ( 2013.01 ) ; A61K 31/711 ( 2013.01) ; State College , PA (US ) ; Pamela A. (Continued ) Basto , Cambridge, MA (US ) ; Michael ( 58 ) Field of Classification Search N. Starnbach , Needham , MA (US ) ; CPC A61K 9/10 ; A61K 35/74 ; A61K 39/39 ; Robert S. Langer , Newton , MA (US ) ; A61K 39/522 ; A61K 39/55555 ; Omid C. Farokhzad , Waban , MA (US ) ; Ulrich Von Andrian , Chestnut (Continued ) Hill , MA (US ) ( 56 ) References Cited (73 ) Assignees: President and Fellows of Harvard U.S. PATENT DOCUMENTS College, Cambridge , MA (US ) ; Massachusetts Institute of 3,960,757 A 6/1976 Morishita et al . Technology , Cambridge, MA (US ) ; The 4,638,045 A 11/1987 Kohn et al . Brigham and Women's Hospital, Inc. , (Continued ) Boston , MA (US ) FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer, the term of this WO WO1997028259 8/1997 patent is extended or adjusted under 35 WO WO1998016247 4/1998 U.S.C. 154 ( b ) by 0 days .
    [Show full text]